Brokerages expect Agenus Inc (NASDAQ:AGEN) to announce $5.77 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Agenus’ earnings, with estimates ranging from $5.00 million to $6.53 million. Agenus posted sales of $8.35 million during the same quarter last year, which would indicate a negative year over year growth rate of 30.9%. The firm is expected to report its next quarterly earnings report on Thursday, March 21st.
According to Zacks, analysts expect that Agenus will report full year sales of $34.04 million for the current financial year, with estimates ranging from $32.50 million to $35.57 million. For the next financial year, analysts expect that the firm will post sales of $10.85 million, with estimates ranging from $5.70 million to $16.00 million. Zacks’ sales calculations are an average based on a survey of analysts that follow Agenus.
Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.04). The business had revenue of $12.80 million during the quarter, compared to analysts’ expectations of $10.76 million.
NASDAQ:AGEN traded up $0.13 on Friday, hitting $2.07. 2,337,152 shares of the stock were exchanged, compared to its average volume of 1,482,957. The stock has a market capitalization of $214.10 million, a P/E ratio of -1.68 and a beta of 2.19. Agenus has a 52 week low of $1.54 and a 52 week high of $6.19.
Hedge funds have recently made changes to their positions in the company. A.R.T. Advisors LLC bought a new stake in shares of Agenus in the 1st quarter valued at about $103,000. Russell Investments Group Ltd. bought a new stake in shares of Agenus in the 1st quarter valued at about $197,000. Jane Street Group LLC bought a new stake in shares of Agenus in the 2nd quarter valued at about $101,000. Barclays PLC increased its stake in shares of Agenus by 95.8% in the 1st quarter. Barclays PLC now owns 73,955 shares of the biotechnology company’s stock valued at $348,000 after acquiring an additional 36,179 shares during the last quarter. Finally, UBS Group AG increased its stake in shares of Agenus by 1,180.3% in the 1st quarter. UBS Group AG now owns 137,417 shares of the biotechnology company’s stock valued at $647,000 after acquiring an additional 126,684 shares during the last quarter. 35.29% of the stock is owned by institutional investors.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Featured Article: Understanding Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.